OTC Markets OTCPK - Delayed Quote USD
Voyageur Pharmaceuticals Ltd. (VYYRF)
0.1000
-0.0250
(-20.00%)
As of May 16 at 4:00:00 PM EDT. Market Open.
Breakdown
TTM
11/30/2024
11/30/2023
11/30/2022
11/30/2021
Total Revenue
0
0
0
0
0
Operating Expense
2,187.9110
1,699.2990
1,346.3790
1,751.9250
2,048.1910
Operating Income
-2,187.9110
-1,699.2990
-1,346.3790
-1,751.9250
-2,048.1910
Net Non Operating Interest Income Expense
--
0
-4.4800
0
-3.2770
Other Income Expense
--
-7.9410
-48.6100
-1.9690
--
Pretax Income
-2,195.8520
-1,707.2400
-1,399.4690
-1,753.8940
-2,051.4680
Net Income Common Stockholders
-2,195.8520
-1,707.2400
-1,399.4690
-1,753.8940
-2,051.4670
Diluted NI Available to Com Stockholders
-2,195.8520
-1,707.2400
-1,399.4690
-1,753.8940
-2,051.4670
Basic EPS
-0.02
-0.01
-0.01
-0.02
-0.02
Diluted EPS
-0.02
-0.01
-0.01
-0.02
-0.02
Basic Average Shares
143,322.1160
137,626.4430
130,503.7730
107,826.0180
94,677.8870
Diluted Average Shares
143,322.1160
137,626.4430
130,503.7730
107,826.0180
94,677.8870
Total Expenses
2,187.9110
1,699.2990
1,346.3790
1,751.9250
2,048.1910
Net Income from Continuing & Discontinued Operation
-2,195.8520
-1,707.2400
-1,399.4690
-1,753.8940
-2,051.4670
Normalized Income
-2,187.9110
-1,699.2990
-1,350.8590
-1,751.9250
-2,051.4670
Interest Expense
--
0
4.4800
0
3.2770
Net Interest Income
--
0
-4.4800
0
-3.2770
EBIT
-2,195.8520
-1,707.2400
-1,394.9890
-1,753.8940
-2,048.1910
EBITDA
-2,194.3920
-1,705.6700
-1,392.8040
-1,744.6840
-2,039.9660
Reconciled Depreciation
1.4600
1.5700
2.1850
9.2100
8.2250
Net Income from Continuing Operation Net Minority Interest
-2,195.8520
-1,707.2400
-1,399.4690
-1,753.8940
-2,051.4670
Total Unusual Items Excluding Goodwill
-7.9410
-7.9410
-48.6100
-1.9690
0
Total Unusual Items
-7.9410
-7.9410
-48.6100
-1.9690
0
Normalized EBITDA
-2,186.4510
-1,697.7290
-1,344.1940
-1,742.7150
-2,039.9660
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
11/30/2021 - 10/19/2017
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade